Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
This is an open-label, multi-site, single-arm Phase 2 study of adjuvant nivolumab combined with ipilimumab for the treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria, without evidence of metastatic disease. All patients enrolled to the study will be treated with nivolumab 240 mg IV every 2 weeks plus ipilimumab 1mg/kg IV every 6 weeks. 1 cycle = 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, patient request to discontinue or completion of treatment. Subjects may receive up to 25 doses of nivolumab and 8 doses of ipilimumab
Melanoma|Ocular Melanoma
DRUG: Nivolumab|DRUG: Ipilimumab
3 year Relapse Free Survival (RFS), RFS is defined as time from registration to recurrence of disease or death from any cause., 36 months
Median RFS, RFS is defined as time from registration to recurrence of disease or death from any cause, 12 months|Overall Survival (OS), OS is defined as the time from registration until death from any cause, 12 months|3 year OS, OS is defined as the time from registration until death from any cause, 36 months|Assess Adverse Events, Grade 3 and 4 toxicities as defined by the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v4, 36 months
This is an open-label, multi-site, single-arm Phase 2 study of adjuvant nivolumab combined with ipilimumab for the treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria, without evidence of metastatic disease. All patients enrolled to the study will be treated with nivolumab 240 mg IV every 2 weeks plus ipilimumab 1mg/kg IV every 6 weeks. 1 cycle = 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, patient request to discontinue or completion of treatment. Subjects may receive up to 25 doses of nivolumab and 8 doses of ipilimumab